Inhibitors of Bruton's tyrosine kinase
View Patent ↗Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
1. A process for the preparation of 1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (compound 4) comprising: treatment of compound 3:
wherein compound 3 exists in the R or S configuration or mixture thereof, with an acid followed by coupling with acryloyl chloride to give compound 4:
wherein compound 4 is in the R or S configuration or mixture thereof.
2. The process of claim 1 , wherein the acid is hydrochloric acid.
3. The process of claim 1 , wherein the acid is hydrochloric acid in dioxane.
4. The process of claim 1 , wherein the process comprises treatment of compound 3 with hydrochloric acid in dioxane, followed by concentration of the reaction to dryness and coupling with acryloyl chloride.
5. The process of claim 1 , wherein compound 4 is washed with aqueous citric acid and brine.
6. The process of claim 1 , wherein compound 4 is purified by flash chromatography.
7. The process of claim 1 , wherein compound 3 exists as a mixture of the R and S configuration and compound 4 exists as a mixture of the R and S configuration.
8. The process of claim 1 , wherein compound 3 exists in the R configuration and compound 4 exists in the R configuration.
9. The process of claim 1 , wherein compound 3 exists in the S configuration and compound 4 exists in the S configuration.
10. The process of claim 1 , further comprising forming a pharmaceutically acceptable salt of compound 4.
11. The process of claim 1 , further comprising reacting compound 4 with an inorganic acid to form a pharmaceutically acceptable salt.
12. The process of claim 11 , wherein the inorganic acid is hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, or metaphosphoric acid.
13. The process of claim 1 , further comprising reacting compound 4 with an organic acid to form a pharmaceutically acceptable salt.
14. The process of claim 13 , wherein the organic acid is acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, trifluoroacetic acid, tartaric acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethanedisulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, toluenesulfonic acid, 2-naphthalenesulfonic acid, 4-methylbicyclo-[2.2.2]oct-2-ene-1-carboxylic acid, glucoheptonic acid, 4,4′-methylenebis-(3-hydroxy-2-ene-1-carboxylic acid), 3-phenylpropionic acid, trimethylacetic acid, tertiary butylacetic acid, lauryl sulfuric acid, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, or muconic acid.
15. The process of claim 1 , wherein compound 3 is prepared by reacting compound 2:
with tert-butyl 3-hydroxypiperidine-1-carboxylate:
under Mitsunobu reaction conditions.
16. The process of claim 15 , wherein the Mitsunobu reaction conditions comprises the use of polymer-bound triphenyl phosphine, diisopropyl azodicarboxylate and tetrahydrofuran.
17. The process of claim 15 , wherein compound 3 is purified by flash chromatography.